Sign In
Buy CNSP
$6.70
-0.200 (-2.90%)
At Close: Nov 17, 2025
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
01:17pm, Monday, 17'th Nov 2025
CNS Pharmaceuticals, Inc. ( CNSP ) Shareholder/Analyst Call November 17, 2025 12:00 PM EST Company Participants John Climaco - CEO, President & Director Christopher Downs - Chief Financial Officer Pre
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
08:35am, Monday, 17'th Nov 2025
Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
09:15am, Wednesday, 03'rd Sep 2025
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:05am, Friday, 15'th Aug 2025
Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUST
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
09:15am, Thursday, 14'th Aug 2025
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical compa
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
08:45am, Tuesday, 22'nd Jul 2025
– Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing i
CNS Pharmaceuticals Announces Reverse Stock Split
08:00am, Friday, 18'th Jul 2025
HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
09:32am, Wednesday, 09'th Jul 2025
HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
08:05am, Thursday, 05'th Jun 2025
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire /
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
08:05am, Friday, 16'th May 2025
Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multi
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
09:35am, Tuesday, 13'th May 2025
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
07:00am, Tuesday, 13'th May 2025
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Manag
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
08:05am, Tuesday, 01'st Apr 2025
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical eff
